Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_assertion type Assertion NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_head.
- NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_assertion description "[Although patients who were found to have LOI of IGF2 were more likely to have advanced stage gastric tumors (P?=?0.04), no statistically significant differences in survival were found based on imprinting status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_provenance.
- NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_assertion evidence source_evidence_literature NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_provenance.
- NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_assertion SIO_000772 21268128 NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_provenance.
- NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_assertion wasDerivedFrom befree-20150227 NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_provenance.
- NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_assertion wasGeneratedBy ECO_0000203 NP483714.RALNbRmkmJbSv3FfbreQ02WLoVes1R-NodQg7ZzVM5dlY130_provenance.